30 January 2019
  • Share

With a growing economy, and a large, ageing population, China is attracting attention from global pharmaceutical and biotechnology companies. China’s home grown therapeutics companies are thriving, benefiting from a large pool of talented researchers, substantial research and development infrastructure, and the potential rewards offered by the world’s second largest pharmaceutical market.

Precision medicine in particular is attracting massive interest, with the government capitalising on its expertise in biotechnology, combined strong track record in computing hardware and the ability to put in place the infrastructure necessary to support large bioinformatics projects. The large population of China is an advantage here, enabling the collection and analysis of a large volume of patient data, creating a powerful database of genetic information. 

The patent system

China’s patent system, however, prohibits the grant of patents to “methods of diagnosis”, and this is interpreted very strictly. Whilst some jurisdictions have restrictions around the grant of patents to methods of diagnosis, there are often specific exclusions. Europe, for example, prevents the grant of patents to diagnostic methods practiced on the human body, but will allow claims to methods practiced on samples previously obtained from those patients, and thus diagnosis by genomic or proteomic analysis are rarely problematic. Similarly, the USA will not grant patents that broadly claim the diagnostic correlation between biomarker and disease (rejecting these as an attempt to monopolise a law of nature), but uses of that correlation, such as in methods of treatment using particular agents can be obtained.  

China, on the other hand, has a very restrictive patent system in this area. This may be at odds with the Chinese government’s investment in the space, as the ability to obtain patents is often cited as incentive for companies to innovate.

Will this result in China missing out on significant precision medicine innovations?

Companies could be unwilling to launch new diagnostic tests on the Chinese market, if they are unable to obtain IP rights to enforce against copycats. However, the scale of the Chinese market may mean that it is just too attractive to pass up, despite the absence of patent protection. As such companies may be required to be smart in how they approach the Chinese market. Innovators may need to be creative in their use of IP to try to protect their innovations as best they can. Companies will be keen to establish strong brand identity around new diagnostic tests launched into the Chinese market, filing appropriate trademarks to protect that brand, rather than the innovation behind test itself. As such, there may be significant first-to-market advantages, where such tests can become established as the standard of care.

Innovators may also seek to develop tests that are bespoke for the Chinese market, to try to develop a product that contains elements such as novel antibodies or testing reagents that are themselves eligible for patent protection. This may mean that the test launched in China includes elements that are new, inventive, and protectable by patents, but which may not actually be the best agent for the job, if commercial considerations are prioritised over patient care.

It will be interesting to see whether the ability to obtain patents in this area develops, as more and more Chinese companies develop technologies in this space. Given the scale of the Chinese market, overseas companies will still be keen to invest. However, innovators should think about their likely patent position in China at an early stage in the development process.

This blog was written by Frances Salisbury and Tanis Keirstead, both members of our dedicated precision medicine team. 

More about Tanis Keirstead

Tanis has over 10 years’ experience drafting and prosecuting patent applications in the pharmaceutical, biotechnology and food & beverage sectors. Tanis works with a wide range of clients on invention capture and filing strategy, as well as global portfolio management. Her clients include SMEs, Universities (in the UK and elsewhere), domestic and overseas multi-national companies, as well as start-ups. Tanis visits Japan several times a year and handles large European portfolios for a number of Japanese companies. Tanis has a degree in Microbiology and Virology from the University of Warwick and a PhD in Molecular Biology from the Sir William Dunn School of Pathology, University of Oxford. Tanis is a member of the Patentanwaltskammer and authorised to provide patent services from Germany. 

Fran is a Partner and Patent Attorney at Mewburn Ellis. She works in all patent cycle stages within the life sciences sector – from invention capture, drafting and patent strategy to prosecution and global portfolio management. Fran is a member of our plant variety rights team, having completed the official WIPO course on plant variety protection under the UPOV convention. As such, she has extensive experience dealing with plant-related inventions, including obtaining plant variety rights and entry onto the national list and common catalogue.

Sign up to our newsletter: Forward - news, insights and features

Our People

Our IP specialists work at all stage of the IP life cycle and provide strategic advice about patent, trade mark and registered designs, as well as any IP-related disputes and legal and commercial requirements.


Contact Us

We have an easily-accessible office in central London, as well as a number of regional offices throughout the UK and an office in Munich, Germany.  We’d love to hear from you, so please get in touch.